Warning: There are an increasing number of fraudulent websites that impersonate ECCMID. We would like to alert all our members and delegates to possible scams and we strongly advise you to use only the official ECCMID online registration for your bookings.

Integrated Symposia


For the full programme of the Integrated Symposia please click here

12:15 – 13:15

AstraZeneca

Protecting vulnerable populations from COVID-19


12:15 – 13:15

Abbott

The lab of the future: how COVID-19 taught us the value of a transcendent laboratory service


12:15 – 13:15

Copan Italia S.p.a

Sample self-collection, a lesson gained during the COVID pandemic


12:15 – 13:15

MeMed

Leveraging the host response to acute infection to create new diagnostic and prognostic tools


12:15 – 13:15

GSK-AMR

A spotlight on antibiotic resistance in community settings: uncomplicated urinary tract infections


13:30 – 15:30

Pfizer

Building on a strong foundation to address a new era to help protect against pneumococcal disease


13:30 – 15:30

GSK

Role of monoclonal antibodies (mAbs) in the evolution of early treatment in COVID-19


13:30 – 15:30

Janssen Pharmaceuticals

COVID-19 vaccines: lessons learnt and prospects in 2022


13:30 – 15:30

Moderna

mRNA science: a paradigm shift to address unmet medical needs


16:15 – 18:15

Pfizer

MDR Gram-negative infections in a pandemic world: contemporary treatment options


16:15 – 18:15

MSD

Best of both worlds: maximising serotype coverage and quality of immune responses for pneumococcal disease prevention


16:15 – 18:15

Bruker Daltonics GmbH & Co KG

Changing microbiology: focus to critical infectious diseases by state-of-art technologies


16:15 – 18:15

SD Biosensor

The usefulness of various Point-of-Care tests against evolving COVID-19


16:15 – 18:15

Menarini Group

Expected impact on clinical outcomes of early identification and early management of MDR Gram-negative infections

08:30 – 10:30

QIAGEN

After the COVID-19 tide: exploring novel approaches in infectious diseases diagnostics from syndromic to immune testing


08:30 – 10:30

MSD

Conquer the case: integrating microbiological testing and the immune status of the host into clinical decision making


08:30 – 10:30

Seegene Inc.

Facing a ‘new normal’: co-existence of SARS-CoV-2 and respiratory virus


08:30 – 10:30

GSK-AMR

A Moment to Reset: harnessing learnings to tackle antimicrobial resistance in the community


08:30 – 10:30

Mundipharma

Spotlight on antifungals: are we well equipped for treating invasive fungal disease?


12:15 – 13:15

AstraZeneca

Staying ahead of the virus: evolving preventative strategies to manage COVID-19 variants


12:15 – 13:15

QuantaMatrix Inc.

Rapid AST on positive blood cultures: new standards in rapid susceptibility testing?


12:15 – 13:15

Tillotts Pharma

Control disease immediately: think C. difficle infection, think COVID!


12:15 – 13:15

Insmed Ireland Ltd

Time to rethink NTM: understanding your at-risk MAC-PD patients and optimising their outcomes


12:15 – 13:15

InfectoPharm Arzneimittel und Consilium GmbH

Intravenous fosfomycin: comprehensive new data evaluation for this WHO essential antibiotic for treatment of adult and pediatric patients with severe infections


13:30 – 15:30

Pfizer

Future-proofing mould disease diagnosis and treatment: the post-pandemic era


13:30 – 15:30

MSD

COVID-19 today: outpatient treatment options and considerations


13:30 – 15:30

Gilead Sciences Europe Ltd

Optimizing treatment of invasive fungal infections in critically ill patients


13:30 – 15:30

Thermo Fisher Scientific

Moving insights into action: how innovative rapid diagnostics impact treatment decisions


13:30 – 15:30

Oxfrod Nanopore Technologies

Evolution of rapid metagenomics for infectious disease applications


16:15 – 18:15

Pfizer

New data, fresh perspectives: an update on CAP and cSSTI


16:15 – 18:15

F2G Ltd

Reviewing 20 years of managing invasive mould infections: lessons learned and remaining challenges


16:15 – 18:15

Menarini Group

In light of the COVID-19 pandemic: how can new antibiotics help reduce the pressure on hospitals and facilitate early discharge?


16:15 – 18:15

Hologic

Innovative and scalable molecular solutions for infectious disease testing


16:15 – 18:15

Sanofi Pasteur

RSV burden: the need for all infant protection

08:30 – 10:30

Pfizer

The science of mRNA COVID-19 vaccines: paving the way for a new prevention paradigm


08:30 - 10:30

Janssen Pharmaceuticals

RSV in adults: the hidden enemy?


08:30 - 10:30

Roche

Ongoing challenges in pandemic management


12:15 – 13:15

T2 Biosystems

Rapid culture-independent diagnostics charting a new course for sepsis management and antimicrobial stewardship


12:15 – 13:15

Siemens Healthineers

Testing for respiratory viruses: a dynamic field in an evolving environment


12:15 – 13:15

Medicago Inc.

The transition from emergency to routine SARS-CoV-2 vaccines: what data do we have and what data do we need?


12:15 – 13:15

Seegene Inc.

How multiplexed molecular testing for infectious disease is evolving


12:15 – 13:15

bioMérieux

Faster ID and AST revolution: how to improve antibiotic use in critically ill


13:30 – 15:30

Pfizer

Fighting COVID-19: how healthcare advances are tipping the scale in humanity's favour


13:30 – 15:30

Gilead Sciences Europe Ltd

The calm after the storm? Antivirals for hospitalised patients with COVID-19 in the post vaccination era


13:30 – 15:30

Shionogi

Treating Gram-negative infections caused by pathogens with limited treatment options: unanswered questions and emerging evidence


13:30 – 15:30

Sanofi Pasteur

Influenza vaccination: protection beyond flu


13:30 – 15:30

Cepheid

Innovating patient care with PCR diagnostics: the fast, the accurate, and the easy


13:30 – 15:30

Abbott

Transitioning to endemic COVID-19 testing: evidence-based assessment on current and future rapid antigen test detection


16:15 – 18:15

Beckman Coulter

Antimicrobial resistance and detection: a continued critical issue


16:15 – 18:15

Sanofi Pasteur

What matters in the fight against COVID-19: how to keep high levels of protection in a multivariant environment?


16:15 – 18:15

Illumina Cambridge

Moving next-generation sequencing to clinical microbiology laboratories: the future is now!


16:15 – 18:15

Shionogi

The current and emerging antiviral landscape for SARS-CoV-2

08:30 – 10:30

RMEI Medical Education

Confronting CMV in the transplant population: applying the guidelines amid new therapeutic options


08:30 – 10:30

GSK (Vaccines)

How can vaccinology impact healthy ageing?


08:30 – 10:30

DiaSorin S.p.A.

Improving patient health care in COVID-19 era


08:30 – 10:30

Novartis

Therapeutic innovations in COVID-19: anti-spike biologics with pan-variant activity


12:15 – 13:15

Medscape LLC

Cytomegalovirus prevention: current challenges and future prospects in CMV